Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03794609 · ClinicalTrials.gov registry record
Observational Study Investigating Clinical & Anthropometric Characteristics of Children With Achondroplasia.
A clinical trial, sponsored by Pfizer.
- Terminated
- Registry status
- 315
- Enrollment target
NCT03794609: Clinical Trial study, sponsored by Pfizer.
NCT03794609 is a clinical trial that was terminated before completion, run by Pfizer. The registered enrollment target is 315 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03794609 was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- 315 participants
- Enrollment target
Study Summary
This is a registry study in children with achondroplasia, age 0-10 years, to be conducted at multiple clinical centers in several countries. Information collected will include in anthropometric characteristics, related symptoms, tests, \& treatments Children's information will be collected in the registry for a maximum of 5 years.
Primary Outcome
Standing height (for participants aged ≥2 years) is an assessment of maximum vertical size. Standing height was measured using a stadiometer with a fixed vertical backboard and an adjustable head piece. Height in supine position (or length for participants aged \<2 years) was measured using measuring board. Three valid measurements were performed at each visit and the average of the 3 valid measurements was reported and used in descriptive summaries. Data is reported according to age group (\<2
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 315 participants |
| Start Date | 2018-06-15 |
| Est. Completion | 2023-01-13 |
Why NCT03794609 stopped before completion
NCT03794609 is an observational study that tracks outcomes without assigning an intervention. The registered 315 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT03794609 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03794609 about?
NCT03794609 is a clinical study titled "Observational Study Investigating Clinical & Anthropometric Characteristics of Children With Achondroplasia.". This is a registry study in children with achondroplasia, age 0-10 years, to be conducted at multiple clinical centers in several countries. Information collected will include in anthropometric characteristics, related symptoms, tests, \& treatments Children's information will be collected in the r...
What is the current status of trial NCT03794609?
This trial is currently terminated. The enrollment target is 315 participants. The study started on 2018-06-15. Estimated completion is 2023-01-13.
Who is sponsoring clinical trial NCT03794609?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04812366 · 315 participants · Phase 2
Genomic Biomarker-Selected Umbrella Neoadjuvant Study for High Risk Localized Prostate Cancer
- NCT05101460 · 315 participants
An All Comers Registry For Normothermic Ex Vivo Lung Perfusion (EVLP) as Assessment of Donor Lungs for Transplant
- NCT05897320 · 315 participants · Phase 3
A Study of Eptinezumab in Pediatric Participants With Episodic Migraine
- NCT06439082 · 315 participants · Phase 3
A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI